Biotech

Sarepta Therapeutics Announces a Continued Benefit on Walking Test Through 62 Weeks in Phase IIb Open-Label Extension Study of Eteplirsen in Duchenne Muscular Dystrophy

CAMBRIDGE, MA: Data to Be Presented at European Neuromuscular Centre Workshop ...

Emerging World Pharma Inc. Strategic Partner African Global Pharma GH Receives Ghana Food and Drug Board Packaging and Insert Approvals for Paracetamol Tablets

SUNYANI, GHANA: ...

Metal Hypothesis for Alzheimer's, Huntington and Other Neurodegenerative Diseases Declared Promising Therapeutic Strategy by Scientists at New York Academy of Sciences Symposium

MELBOURNE, AUSTRALIA: ...

Cerecor Announces Option to Johns Hopkins Brain Science Institute DAAO Inhibitor Platform

BALTIMORE, MD: ...

Peregrine Pharmaceuticals Announces Significant Progress in Advancing Its Cotara Program Into a Pivotal Phase III Trial

TUSTIN, CA: Agreement Reached With FDA on Pivotal Trial Design for Its Novel Targeted Therapy Cotara for the Treatment of Recurrent Brain Cancer; Agreement Allows for Phase III Trial Planning While Advancing Part ...

Pharma-Bio Industry Expects to Wrap Up $12.6 Billion in 2012 North American Capital/MRO Investments, an Industrial Info News Alert

SUGAR LAND, TX: ...

Leading Biotech Company Selects Dataflow Manager(TM) for Multiple Clinical Programs

CAMBRIDGE, MA: Implemented as an Enterprise Solution to Support Multiple Trial Outsourcing Models ...

Thallion Obtains Conditional Approval to List on the TSX-V and Concurrently Applies to Voluntarily Delist From the TSX

MONTREAL, QUEBEC: ...

Marina Biotech Receives Key Patent Issuance From the USPTO for Its Unlocked Nucleobase Analog (UNA) Chemistry

BOTHELL, WA: Patent Broadly Covers RNA-Based Oligonucleotide Therapeutics Containing a UNA ...

Peregrine to Report Second Quarter Fiscal Year 2013 Financial Results After Market Close on December 10, 2012

TUSTIN, CA: ...